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Summary Proliferative and secretory responses in androgen-sensitive prostate cancer LNCaP cells are regulated by steroid and peptide
hormones and by differentiation-promoting substances. In the present study, we evaluated whether peripheral blood monocytes that exhibit
anti-tumour activity in haematopoietic and solid tumours influence growth and secretion in the LNCaP cell line. For this purpose, LNCaP cells
were incubated with monocyte-conditioned medium (MCM), and proliferation as well as expression of androgen receptor (AR) and secretion
of prostate-specific antigen (PSA) were assessed. Conditioned medium from monocytes reduced proliferation in a dose-dependent manner.
Incubation with 40% MCM caused a 50% reduction in cell proliferation. AR protein decreased by 70% and PSA levels in supematants from
LNCaP cells were reduced by approximately 80% following treatment with MCM. We focused on the contribution of two major products of
activated monocytes, prostaglandin E2 and interleukin 113 (IL-15), to the MCM modulatory action. LNCaP cells treated with prostaglandin E2
showed neither a reduction in proliferation nor a down-regulation of AR and PSA levels. The effects of MCM on cellular proliferation, AR
protein and PSA secretion were abolished by pretreatment of MCM with a neutralizing anti-IL-13 antibody. In addition. recombinant IL-15 was
able to replace MCM for the inhibition of proliferation and down-regulation of AR and PSA proteins. LNCaP cells were shown to express the
IL-1i receptor type 1, which transduces IL-13 signal. Our findings reveal that monocyte-derived IL-1i inhibits the proliferation of androgen-
responsive prostate tumour cells and reduces AR and PSA levels.
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The LNCaP cell line. which xas derived from a lymph node
metastasis ofa patient who did not respond to endocrine therapy. is
frequently used as a model for studying human prostate cancer
(Horoszexxicz et al. 1983). It is know-n that steroid and peptide
hormones as well as differentiation-promoting substances regulate
proliferative and secretorv responses in LNCaP cells. The cells
respond to androgen stimulation by acceleratinc division and
producing prostate-specific antigen (PSA). The patterns of andro-
aenic reaulation of growth and secretory function in the LNCaP
cell line are different (Lee et al. 1995). The maximal growth rate is
achiexed at 0.1 nm of dihydrotestosterone (DHT). whereas higher
doses of this androgen induce grow-th arrest. It was proposed that
the inhibition of cellular proliferation by high androgen doses is
mediated by transforming growth factor j (TGF-P) (Kim et al.
1996). In contrast to the proliferative response. the percentage of
PSA-positix e cells and the levels ofPSA protein in LNCaP super-
natants increase at concentrations of 1 nmi dihydrotestosterone and
bevond (Lee et al. 1995). In addition to androgens. polypeptide
growth factors such as epidermnal growth factor (EGF). TGF-at.
insulin-like growth factors and basic fibroblast growth factor
(bFGF) are mitonenic for LNCaP cells (Wildinn et al. 1989:
MacDonald and Habib. 1992: Nakamoto et al. 1992: Ritchie et al.
1997). Positixe effects oftriiodothvronine and inhibitorx effects of
xitamin D. retinoic acid. luteinizin5 hormone-releasing hormone.
phenylacetate and actixin on grrow-th of LNCaP cells has-e also
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been described (Limonta et al. 1992: Skoxxronski et al. 1993:
Young et al. 1994: Esquenet et al. 1995: Dalkin et al. 1996: Walls
et al. 1996). Secretion of PSA ,A-as found to be enhanced after
treatment with triiodothvronine. vitamin D and phenylacetate
(Skowronski et al. 1993: Esquenet et al. 1995: W'alls et al. 1996).
wxhereas divergent results on PSA regulation by retinoic acid wA-ere
reported (Fona et al. 1993: Youna et al. 1994. LNCaP cells
express a mutant androgen receptor (AR). wxhich binds oestrogenic
and progestagenic steroids and non-steroidal anti-androgens
hN-droxvflutamide and nilutamide with hiaher affinitv than the
wild-type AR. These substances induce reporter gene actixitx in
the presence ofLNCaP AR more efficientlI than in the presence of
the %vild-trpe AR (Veldscholte et al. 1990).
Studies on interactions between leucocytes that produce Xarious
cvtokines and differentiation factors and prostate tumour cells max
improve understandinc of prostate cancer biologx. In one of the
initial studies in this field Hsieh et al (1995) have shoxxn that
phytohaemagglutinin (PPHA)-stimulated lymphocvtes produce
substance(s) that reduce cell prohiferation. increase expression of
cytoskeleton proteins and down-regulate AR and PSA in LNCaP
cells. These effects A-ere obserxed after treatment with xarious
concentrations of T-lymphocyte-conditioned media (TCM1).
Hoxxexer. the T-cell-derixved factor(s) that mediate these effects
hax e so far not been identified. Interactions betxween other cells of
the immune system and various tumours haxe been described
(Wang et al. 1996: Iversen et al. 1997). For example. monocvtes
were found to suppress cell viability and colony formation in
human leukaemias and lung tumours. In this study. we address the
issue of whetherperipheral blood monoc tes influence groxxth and
secretion in androoen-responsive prostatic epithelial cells. We
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showx that monocyte-derived interleukin 1 B (IL-I5> is a mediator
of the modulatory effects on LNCaP cells.
MATERIALS AND METHODS
Materials
MCDB-131 and RPMI-1640 media w-ere purchased from Sigma
(Deisenhofen. Germany) and HyClone (Logan. UT. USA) respec-
tivelv. Fetal calf serum (FCS) and antibiotics (penicillin/strepto-
mxcin) were from Biological Industries (Kibutz Beth Haemek.
Israel). Phosphate-buffered saline (PBS) %vas from PAA
Laboratories (Linz. Austria). Cell culture Xessels were from Costar
(Cambridge. MA. USA). Sarstedt (Niimbrecht. Germanv) and
Falcon (Lincoln. NE. USA).
Phvtohaemaaalutinin-M (PHA-M) ,A-as purchased from Difco
Laboratonres (Detroit. MA. USA). The murine monoclonal anti-
cvtokeratin 8 and 18 antibodx CAM 5.2 was purchased from
Becton Dickinson (San Jose. CA. USA) and a polyclonal rabbit
anti-IL-l[ antibodv from Genzyme (Cambridge. MIA. USA). The
mouse monoclonal antibody MEM18 (IgG1 anti-CDl4) was from
An Der Grub. Vienna. Austria. Biotinvlated monoclonal antibodx
6B5 (IgG2a anti-IL-I receptor type I) was purchased from
PharMingen (San Diego. CA. USA). Both radiolabelled (specific
activitx 83.2 Ci mmol- ) and unlabelled svnthetic androgen
methvltrienolone (R 1881) were purchased from New England
Nuclear (Dreieichenhain. Germany). IL-i x-as provided by
Sigma. Prostaglandin E, was from Boehringer Ingelheim
(Heidelberg. Germanv). The scintillation liquid Optiphase was
from Pharmacia (Uppsala. Sw-eden). The commercial methv-l-
thiotetrazole (M`T7) assay E4ZU was purchased from Biomedica
(Vienna. Austria). An immunoenzymetric assay for the quantita-
tive measurement of human IL-1, (minimum detectable concen-
tration 2 pg ml-') w-as proxided by Medgenix Diagnostics (Fleurus.
Belgium). The PSA lMx enzyme immunoassav (sensitixvitv 0.1 no
ml') w-as from Abbott Laboratories (Abbott Park. IL. USA).
FACS Calibur apparatus and CellQuest softw-are were from
Becton-Dickinson.
Culture of peripheral blood monocytes
Peripheral blood was collected from three healthy volunteers on
several occasions. Monocvtes were obtained from peripheral
blood mononuclear cells after Ficoll separation by standard adher-
ence (90 min. 37-C( and cultured in RPMI-1640 medium that was
supplemented wxith 10%e charcoal-stripped FCS (CS FCS). The
purity ofmonocytes as determined by staining for naphthol acetate
esterase and by measuring CD14 expression wxas > 90%. For
preparation of monocyte-conditioned medium (NICM). 2.5 x 10-
monocvtes ml-' were cultured w-ith and x-ithout PHA. After 48 h.
the supernatants were cleared by centrifugation and frozen at
- 20 C until use.
Proliferation assays in LNCaP cells
The LNCaP cell line w-as purchased at passage 21 from the
American Type Culture Collection (Bethesda. MD. USA). LNCaP
cells were seeded into 24-svell plates at 2 x 10- cells per well in
MCDB-131 medium supplemented with 10%7e FCS. Medium wxas
changed 24 h later and the final concentration of CS FCS was
3%. Culture medium >-as supplemented with MCM (10-60%c.
prostaglandin E, (I-i0l.tM) or IL-l1 (0.1-lOng ml Control
experiments w-ere carried out in the absence of any supplement in
medium or in the presence of PHA-M. In neutralization experi-
ments. MCM w-as preincubated with the antibody against IL-1,B
oxvernight. It has prexiously been determined that I mg of this
antibody is capable of neutralizing approximately 1000 units of
natural or recombinant IL-1P. Cell proliferation A-as determined
after 72 h incubation by means of the MITT assax. This assax is
based on the abilitv of lixini cells to reduce slightly coloured
tetrazolium salts to intensely coloured formazan derixatixves. The
assay wxas performed as described previously (Cronauer et al.
1996). In selected experiments the MTT assav results Awere
compared w-ith those obtained with a cell counter and were found
to be identical.
Immunohistochemical analyses
Following treatment with MCNI or medium without supplements.
LNCaP cells were trxpsinized. cytospun. resuspended in PBS.
fixed in 1% paraformaldehx de. permeabilized by adding 0.1%c
Triton X-100 and stained for cvokeratin expression. Cy-tokeratin
immunohistochemistry was performed according to a strepta-
xidin-biotin-peroxidase protocol. The immunohistochemical
procedure Axas described prexviously (Hobisch et al. 1995).
Androgen receptor-binding assay
LNCaP cells w-ere cultured in the absence (untreated control) or
presence of respective supplements in 5%c CS FCS for 72 h. Then
they were scraped off. washed once. resuspended in medium and
incubated with ['H]methyltrienolone. at concentrations of 0.3-
5 nst. for 90 min at room temperature. Non-specific bindingxwas
measured in the presence of a 200-fold molar excess of unlabelled
methxItrienolone. The pellets w-ere recoxered after incubation by
centrifugiation (3800g. 3 min) and w-ashed twice w-ith 500 gl of
ice-cold medium. The cell pellets w-ere then lysed in 1 ml of scin-
tillation liquid and the radioactix ity \-as determined in aP-counter.
Cellular protein w-as determined according to the method
described by Bradford (1978). B and K, wxere calculated by
Scatchard analx sis.
Determination of prostate-specific antigen in
supematants from LNCaP cells
The cells were grown on 24-%vell plates in the presence of5% CS
FCS w-ith or x ithout supplements. The medium A-as remoxved after
72 h and the PSA lexvel x as measured by an enzy me immunoassax.
PSA Xalues xxere corrected for cell numberaccording to the results
ofthe proliferation assay.
Determination of IL-1,B concentration in monocyte
conditioned media
IL-1 in MCM was determined by a solid-phase enzyme amplified
sensitivity immunoassav. The assay is based on an olicoclonal
sx stem in vvhich sexeral monoclonal antibodies directed a2ainst
distinct epitopes of IL-iI5 are used. The use of sexeral distinct
monoclonal antibodies avoids assay hyperspecificity. The assay
xxas performed on a microtitre plate. Samples containing IL-i
react with capture antibodies coated on a plastic xxell and with
monoclonal antibodies labelled wxith horseradish peroxidase. After
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Figure 1 Phenotypic charactenzatin of penpheral blod monocytes and
LNCaP cells. Monocytes (A) and LNCaP cells (B) were labelled with
monoclonkk antibodies specific for the antigen indicated follwed by FITC-
conjugated secondary antibody. and surface expression (bold lines) was
determined with a flow cytometer as described in Maternals and methods.
Isotype-matched antibodies were induded as controls (dotted lines).
Fluorescence intensity (x-axis) is plotted against the number of cells (y-axis)
an incubation penrod of 2 h at room temperature the microtitre
plate was washed three times to remove unbound enzyme-labelled
antibodies. The revelation solution (tetramethylbenzvdine-
hydrogen peroxide) was added and incubated for 15 min at room
temperature. The reaction was stopped with sulphuric acid and the
microtitre plate was read at 450 nm. The concentrations of IL-1o
in MCM ranged between 1.6 and 2.4 ng ml-'.
Measurement of surface antigen expression by flow
cytometry
To determine surface antigren expression. penpheral blood mono-
cvtes were labelled with primary mouse monoclonal anti-CD14
antibody MEM18 followed bv fluorescein isothiocyanate (FITC)-
conjugated goat anti-mouse Ig. LNCaP cells were labelled with
biotinylated primary mouse monoclonal anti-IL-1 receptor anti-
body 6B5 followed by FHTC-conjugated streptavidin. Washes were
in PBS containing 0.2'% boxine serum albumin (BSA). After the
last wash. the cells were stored in PBS containing 0.2%7c BSA and
2%7c formaldehyde. The samples were analysed on a FACS Calibur.
Data were analysed and presented using CellQuest software.
Figure 2 Morphology of untreated (A) and MCM-treated (B) LNCaP cells.
MCM-treated cells are elongated and exhibit dendrite-like processes. which
are indicated by arrows (original magnification x 100)
RESULTS
Monocyte-conditioned medium-treated LNCaP cells
show changes in cell shape
To study the influence of monocv-tes on prostate cancer cells.
LNCaP cells w-ere exposed to medium conditioned by peripheral
blood monocytes homogenously positive for CD14 (Firure 1A).
Distinct morphological changes in LNCaP cells were observed
after treatment with monocyte-conditioned medium (MCM). The
cells became elongated and showed dendrite-like processes. hich
were connected to each other (Figure 2). These morphological
changes were notable even Awith 10%7 MCM in LNCaP culture
medium. Expression of cytoskeletal proteins w-as evaluated by
semiquantitatixe immunohistochemistr-. A monoclonal antibodv
directed against luminal cy-tokeratins 8 and 18 was used for this
purpose. The expression and staining intensit- of these cvtoker-
atins 'Aere previously reported to increase in the more differenti-
ated prostatic luminal epithelium (Peehl et al. 1993). In the case of
LNCaP cells treated with MCM. we obserxed neither an increase
in the percentagre of cytokeratin-immunopositive cells nor a
change in staining intensitv.
British Joumal ofCancer (1998) 78(8). 1004-1011 C 0 Cancer Research Campaign 1998Interleukin-1,B effects on prostate tumourcells 1007
150
_
0-
.o 0i
0-
100
50
0
12
*
0 2
o o o 0 c,
oo
C\J CO I'll
0
T
0O
6 0
c 11
9
0
Figure 3 The effects of increasing concentrations of MCM on proliferation of
LNCaP cells. The cells were incubated with MCM for 72 h and cell
proliferation was assessed by the colorimetric MTT assay. Four
measurements were performed. The results are expressed in per cent of
untreated cells, which were set at 100%. Mean values and standard
deviations were calculated. *P < 0.05, MCM treatment vs untreated cells (0)
and R1881 + MCM vs R1881, Mann-Whitney U-test
Monocyte-conditioned medium causes a
dose-dependent reduction in cellular proliferation
LNCaP cells were cultured in the absence orpresence ofMCM for
3 days. After this period, cellulargrowth was assessed by means of
the MTT assay. Conditioned medium from PHA-M-activated
monocytes reduced cellular proliferation in a dose-dependent
manner (Figure 3). MCM at 40% reduced proliferation by 50%.
Higher concentrations of MCM in culture media did not result in
any further reduction in cell number. PHA-M itselfdid not display
any effect on the proliferation of LNCaP cells. Conditioned
medium from monocytes that were not treated with PHA-M
induced a similar decrease in cell proliferation (data not shown).
Thus, it seems that the presence of PHA in monocyte cultures is
notrequired for inhibition ofgrowth ofLNCaP cells. The prolifer-
ative effect of 0.01 nM of R1881 was abolished by 40% MCM
(Figure 3).
Androgen receptor levels and PSA secretion decrease
after treatment with MCM
Specific binding of radioactively labelled methyltrienolone in
MCM-treated LNCaP cells as well as in controls was determined.
MCM caused a dose-dependent reduction in androgen binding.
Figure 4 shows a decrease in specific binding of [3H]R1881 in
cells treated with 40% MCM. The maximum decrease in the AR
level was approximately 70% in the presence of40% MCM. There
was no change in AR binding affinity following MCM treatment.
Secretion of the AR-regulated PSA protein was measured in
supernatants from LNCaP cells after 72 h of incubation with
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Figure 4 Methyltrienolone binding in untreated (control) and MCM-treated
LNCaP cells. After 72 h of MCM treatment, LNCaP cells were incubated for
90 min with increasing concentrations of [3H]-methyltrienolone. Non-specific
binding was measured in the presence of a 200-fold molar excess of
unlabelled methyltrienolone. The cells were washed twice with ice-cold
medium and specific binding was determined. 0, Control, Kd = 1.1 nmol, Bmw,,
= 0.60 fmol .g-' protein; 0, 40% MCM, Kd = 1.0 nmol, B,,,, = 0.16 fmol g±g-1
protein
MCM. A decrease in PSA was observed in the presence of
20-40% of MCM in culture media. PSA protein was reduced by
80% with 40% MCM. MCM also antagonized stimulatory effects
ofthe synthetic androgen R1881 on PSA secretion into the super-
natant (Figure 5).
IL-1i is responsible for the modulatory effects of MCM
We focused on the contribution of individual factors to the
MCM modulatory effects. Initially, we investigated the role
of prostaglandin E2, which is a major product of activated mono-
cytes (Venkataprasad et al, 1996). LNCaP cells treated with
prostaglandin E2 showed neither a reduction in proliferation nor a
down-regulation of AR and PSA levels. Thus, prostaglandin E2
can be excluded as a mediator of the inhibitory effects of mono-
cytes on androgen-responsive prostate cancer cells. Next, we
examined the role of the proinflammatory cytokine IL-1p, which
exhibits anti-tumour activity in several models (Kilian et al, 1991;
Braunschweiger et al, 1996), in the interaction between the
immune system and prostate cancer cells. In order to determine
whether IL-11 mediates MCM effects on LNCaP cells, MCM was
preincubated with a neutralizing polyclonal anti-IL-l,B antibody.
The effectiveness ofthis antibody was previously demonstrated in
other assay systems (Salem et al, 1990; Lisak and Bealmear,
1991). MCM pretreated with the antibody did not reduce LNCaP
cell proliferation (Figure 6A). The MCM effect on AR protein was
completely abolished after preincubation of MCM with the poly-
clonal anti-IL-15 antibody (Figure 6B), and the PSA levels were
almost completely restored (Figure 6C). Moreover, addition of
recombinant IL-1P to cultures ofLNCaP cells exerted effects that
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Figure 5 Regulation of PSA secrebion in LNCaP cells by MCM. The cells
were incubated in the absence or presence of MCM for 72 h. PSA levels
were measured by an enzyme immunoassay and normalized according to
cell proliferation as assessed by means of the MTT assay. Data are
expressed as nanograms of PSA per unit of absorbance at 450 nm (UA).
Mean values and standard deviations were calculated from four independent
expeniments. *P < 0.05. MCM treatment vs untreated cells (0) and
R1881 + MCM vs R1881. Mann--Whitney UJ-test
werealmst dentical to those of MCM.
Cellproliferatio'
xa
reduced dose dependently (Figure 6A). the AR protein lexvels
decreased (Figure 6D3) and PSA secretion xxas dirminished (Ficrure
6C(. Finally. LNCaP cells xxere shoxxn to express the IL-l13
receptor type I (Figure 1B). xxhich transduces IIL-113 sigrnal (Curtis
etal. 1989).
DISCUSSION
T'he major findingr of the present study is that peripheral blood
monocytes are capable of modulating, cellular exvents in androgen-
responsixve LNCaP cells by secretingr IL-113. This ability of mono-
cv-tes is similar to that prexviously reported for T lymphocytes in
the same cell line (Hsieh et al. 1995). Both cell types secrete
substances that cause a reduction in cellularproliferation. diminish
lexvels of AR protein and doxxn-regulate PSA in LNCaP cells. In
our experiments. MCM was effective regardless of the presence of
PHA in monocvrte cultures. In contrast. unstimulated lymphocytes
provoked only, a minimal growth inhfibition ofLNCaP cells (Hsieh
etal. 1995).
LNCaP cells became elongated and exhibited dendrite-like
processes after contact xxith MCMI and TC.M. Similar changres in
cell shape xxere described after treatment of LNCaP cells xxith
analogues of cAMP (Bang, et al. 1994). There was, however, one
difference betxxeen MCM- and TCM-treated LNCaP cells. The
expression of cy-tokeratins 8 and 18 and their staining intensity
increased twofold after incubation xxith TCM as determined by% a
tota intensitV score procedure (Hsieh et al. 1995). In the case of
MCM xxe did not see any differences in the expression of these
cytoskeleton proteins by semiquantitatixve immunohistochemisti-x.
Contrasting, results on expression of cytokeratins may be due to
use of different antibodies and immunohistocheniical techniques.
It wxas suggaested bv others that 1CM- and cAMP analogyue-treated
LNCaP cells undergo neuroendocrine differentiation (Bang et al.
1994: Hsieh et al. 1995). TCM treatment proxoked an increase in
total intensity score of twxo neuroendocnine mark-ers. neuron-
spcfi'c enolase and serotonin. Hoxx ever, the concept of neuro-
endocrine differentiation of this cell line wvas questioned recently
(Noordzij et al. 1996). In that publication and in our prexvious
expenimental studies neuroendocrine cells within the LNCaP cell
line were not identified (unpublished data). Thus. a differentiation
process induced by leucocytes in androgen-responsixve prostate
cancer cells is not well characterized to date.
T'he MCM-induced growth-inhibitory effect wxas associated
with decreased AR expression. Association betwxeen AR expres-
sion and ggrowth regulation of prostate cancer cells can be studied
in AR-positive LNCaP cells and in AR cDNA-transfected PC-3
cells. Itwxas demonstrated that the expression of AR in PC-3 cells
leads to a decrease in proliferation (Yuan et al. 1993). We infer that
more reliable information on AR involvement in garowxth regulation
may be obtained in its natural cellular environment. i.e. in LNCaP
cells. Growth inhibition and AR reduction A-ere prexviouslx
observed in LNCaP cells incubated wxith retinoic acid and TCM
(Youngy et al. 1994: Hsieh et al. 1995). Regarding AR expression.
conditioned media from T lymphocytes and monocytes. and
reioicd differ from anti-androgens cyproterone acetate.
hNdrox,%flutamide and bicalutamide.wxxhich are commonlv used in
endocrine therapy for prostate cancer. These compounds bind to
the AR wxith low- aff-inity and do not permit acquisition of a tran-
scriptionally actixve form of the receptor (Kemppainen et al. 1992:
Kallio et al. 1994). Howxever, they did not down-regulate AR
protein itself. AR is express-ed in relapsed prostate tumours and in
their metastases. wxhich wxere obtained before onset oftherapy and
durnenc tumour progression (van der Kxx ast et al. 1991: Hobisch et
al. 1995. 1996). Several recent publications support the viewx that
reduction in androgren concentration is not sufficient to prexvent
transmission of extracellular signals xia the AR (Veldscholte et al.
1990: Culig, et al. 1993. 1994: Kokontis et al. 1994: Nazareth and
Weigel1. 1996). Prostate cancer cells may adapt to an enxvironment
A-ith verx lowx androgzen concentration by increasing their AR
expression and transcriptional actixvity (Kokontis et al. 1994).
Furthermore. mutant ARs discoxvered in prostate cancer frequently
exhibit a gain in function: they are efficiently actixvated bx other
steroi C ds and non-steroidal AR antagonists (Veldscholte et al. 1990:
Culig, et al. 1993). Finally. AR activitv isu-eulated by sexveral
non-steroi'dal substances such as polvpeptide groxwth factors and
second messengers (Culig et al. 1994: Nazareth and Weigel. 1996)
Therefore. strategies aimed at reducing, AR lexvels. such as admin-
istration of secretor-v prodlucts from the immune cells. may be
beneficial in metastatic prostate cancer. AR dowxn-regulation was
followed by reduction of PSA protein in LNCaP supernatants.
Thus. the effect of MCM is different to that of phenylacetate and
xvitamnin D. substances that haxve been reported to inhibit prolifera-
tion ofLNCaP ceHls and increase PSA secretion (Walls et al. 1996:
Zhaoetal. 1997).
T'he mediator role ofIL-113 was rexvealed in experiments inxwhich
the neutralizing, anti-IL-113 antibody abolished the effects of MCM.
Furthermore. IIL-I13 itself exhibited a dose-dependent inhibition on
LNCaP prohferation. AR protein lexvel and PSA secretion. In
contrast to our findings wxith MCM'v. a compound that is responsible
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Figure 6 The effects of pretreatment of MCM with the neutralizing polyclonal anti-IL-1i antibody and the effects of IL-1i on (A) proliferation. (B. D) cellular AR
protein levels and (C) PSA protein in supematants of LNCaP cells. Four independent experiments were performed. (AB. antbody): A. C 'P < 0.05. IL-1i
treatment vs untreated cells (0) and antibody pretreatment vs treatment without antibody. Mann-Whitney U-test. B. D: ^. Control. K = 1.0 nmol.
B-a
= 0.62 fmol ug protein: _. 4000MCM. K = 1.6 nmol. B
a
= o.19 fmol ug protein: *. 400o MCM + AB. K = 1.2 nmol. B__ = 0.60 fmol ug- protein
for the arowth-modulatorv effects ofTCM on androgen-responsiVe
prostate cancer cells has not been identified. Antibodies against
TNT-ct. TGF-J. FGF. EGF and IL-2. 4. -5. -6 or -8 vwere tested. but
none ofthem A-as capable ofneutralizing, TCM effects (Hsieh et al.
1995). Based on semipurification of growth-modulatory activity. it
w-as proposed that a protein in the molecular wveight range of 13-
24 kDa is responsible for TCM action. It is not unlikelv that
orowth-modulatorv effects of TCNI and MICM could be. at least in
part. attributed to the same cytokine.
Monocvtes are know-n as the major source of secreted IL-1
(Dinarello. 1988). Human IL- 1 is a 17-kDa protein that is secreted
durinnc an inflammatory process. Tw-o functionally almost equiva-
lent forms of IL-1. IL-lct and IL-1,B. xxhich display about 27%-
homologx at the protein lex el. exist. Both forms of IL- I bind to the
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same cell-surface receptor and therefore show- similar biological
activities. IL-I was found to exhibit anti-tumour activity- in various
neoplasms either by augmentation of cellular immune response or
by inhibition ofproliferation (Braunschweiger et al. 1988: Kilian et
al. 1991). In aareement with our results. IL-1 was previously found
to provoke a dose-dependent growth inhibition in LNCaP cells
(Hsieh and Chiao. 1995: Ritchie et al. 1997). IL-I diminished DHT
effect on the proportion of the replicating LNCaP cells (Hsieh and
Chiao. 1995). However. our results with recard to AR bindine
differ from those of Hsieh and Chiao. These authors failed to show
a negative effect on AR protein levels after IL-1a treatment.
Ritchie et al (1997) also treated LNCaP cells and androgen-
independent PC-3 and DU-145 cells with increasing concentrations
of IL-1[. Supplementation of prostate cell cultures with IL-15
caused a decreased proliferation ofall three cell lines. However. the
negative effect of IL-1[ on proliferation was far more pronounced
in LNCaP cells than in the two androgen-independent cell lines.
Although determination of AR protein was not performed in that
studv. a mark-ed effect in LNCaP cells suggyests an interaction
between IL-1 [ and AR pathways. IL-1[ also decreased cell chemo-
taxis in the three prostate cancer cell lines (Ritchie et al. 1997).
Interestingly. inhibition ofgrow%th of MCF-7 breast cancer cells by
IL-1 is associated with down-regulation of oestrogen receptor
(Danforth and Sgagias. 1991)
A different type of interaction between monocvtes and LNCaP
cells was recently reported (Klein et al. 1997). Expression of
matrilvsin. which is a member of the matrix metalloproteinase
superfamily. in LNCaP cells is induced by conditioned medium
from the monocvtic cell line THP-1. In addition. recombinant IL-1
up-regulated matrilysin expression. Biolo2ical neutralization
experiments revealed that the effect ofTHP-1 conditioned medium
was abolishedby an anti-IL- [3 antibody. and it was concluded that
IL-I [3 is a mediator of matrilysin induction. This up-regulation of
matrilysin by IL-i may be harmful in prostate cancer. It was
shown that matrily-sin-transfected prostate cancer cells have a hich
invasive potential in immunodeficient mice (Powell et al. 1993).
IL- [3 activates several second-messen-er systems in target
tissues (Munoz et al. 1990: Roberts et al. 1992: Carman-Krzan and
Wise. 1993: Cole et al. 1995: Sjoholm 1995). For example. IL-I[
induces cAMP in human decidual cells. It stimulates secretion of
nerve Lrowth factor in astrorlial cultures by activation of the
phospholipase A2-lipoxygenase pathway. In pancreatic [cells
ceramide may be invol-ed in transducing the cvtotoxic and cvto-
static actions of IL-1[3. Involvement of protein kinase C and nitric
oxide pathways in IL-1[ signalling was also described. It remains
to be determined in future studies which of these sianalling path-
ways may be operative in prostatic epithelial cells.
In summary. this studv demonstrates that the monocvte secre-
torn product IL-i [3 is a potentially important negative regulator in
LNCaP cells. Therapeutic application of this pleiotropic cvtokine
in prostate cancer will probably be further explored.
ACKNOWLEDGEMENTS
This work was supported by rrants SFB 002 F203 and P 10 132-
MED of the Austrian Science Foundation (FAT). The excellent
technical assistance of G Sierek. H Linnert. G Holzl. E Tafatsch.
M Karches-Bohm and P Dertschnig and the editorial assistance
of M. Trebo. K. Smekal and Ni. Neuhauser are gratefully
acknowledged.
REFERENCES
Bang YJ. Pirnia F. Fang W-G. Kang W-K. Sartor 0. Whitesell L. Ha MJ. Tsokos NM.
Sheahan MD. Nguven P. Niklinski A-T. NI ers CE and Trepel JB (1994)
Terminal neuroendocn-ne differentiation of human prostate carcinoma cells in
response to intracellular cyclic .AMIP. Proc Narl .4Acad Sci US.A 91: 5330- 334
Bradford NM 1978 A A rapid and sensitive method for the quantitation of microgram
quantities of protein using the principle ofprotein-d\e binding. Anal Bilochem
72: 248-254
Brauns,chwei=er PG. Johnson CS. Kumar N. Ord V and Furmanski P 1988
Antitumor effects ofrecombinant human interleukin 1 alpha in RIF- I and
Panc'2 solid tumors. CancerRes 48: 6011-6016
Carman-Krzan M and Wise BC (1993) Arachidonic acid lipox% genation may
mediate interleukin- 1 stimulation of nerve growth factor secretion in astroelial
cultures. J Veurosci Res 34: 225-232
Cole OF. Seki H. Elder MG. Sullivan Nfl-IF 1 199'5) Interleuk-in- 1P independentl%
stimulates production ofprostaglandin E2 and cyclic AMP from human
decidual cells. Biochim Biophys .4cta 1269: 139-144
Cronauer NW' Klocker H. Talasz H. Geisen F. Hobisch A. Radmavr C. Bock G.
Culiz Z Schirmer NI. Reissiel A. Bartsch G. Konswalinka G 1996) Inhibitor,
effects of the nucleoside analogue eemrcitabine on prostatic carcinoma cells.
Prostate 28: 172-181
Culie Z. Hobisch A. Cronauer NV Cato ACB. Hittmair A. Radmavr C. Eberle J.
Bartseh G. Klocker H (1993) Mutant androgen receptor detected in an
advanced-stage prostatic carcinoma is acti\ated bv adrenal androgens and
progesterone. Moul EEndtcrninol 7: 1541-1550
Culie Z. Hobiseh A. Cronauer MVN: Radmaxr C. Trapman I. Hittmair A. Bartseh G.
Mocker H (1994) Androoen receptor acti\ation in prostatic tumor cell lines b\
insulin-like 2rowth factor-I. keratinocyte growth factor and epidermal growth
factor. Can-er Res 54: 5474-5478
Curtis BNIM Gallis B. O-erell RW. NMcNMahan CJl deRoos P. Ireland R. Eisenrran J.
Dowser SK. Sims JE ( 1989) T-cell interleukin I receptor cDNA expressed in
Chinese hamster ovarv cells regulates functional responses to interleukin 1
Proc Natl .Acad Sci US.4 86: 3045-3049
Dalkin AC. Gilrain IT. Bradshas% D. M1 ers CE (1996) Activin inhibition ofprostate
cancer cell -rowth: selecti\e actions on androgen-responsis e LNCaP cells.
Endocrinologl 137_5''0-23
Danforth DN Jr and S2ace,i&s NMK (1991) Interleukin alpha blcx-ks estradiol-
stimulated growth and dow-n-regulates the estrogen receptor in MCF-7 breast
cancer cells in vitro. Cancer Res 51: 1488-1493
Dinarello CA (1988) Bioloes of interleukin I. FASEB J2: 108-115
Esquenet NM. Ssinnen JY. Heyns W. Verhoeven G (1995) Triiotdoth\ronine
modulates growth. secretor\ function and androgen receptor concentration in
the prostatic carcinoma cell line LNCaP tfol CellEndocrinol 109: 105- 1
Fong CJ. Sutko%%ski DNI. Braun EJ. Bauer KD. Shers\ ood ER. Lee C. KozloA ski JNI
(1993) Effect of retinoic acid on the proliferation and secretor\ actiis-it of
androgen-responsise prostatic carcinoma cells. J Urol 149: 1190-1194
Hobiseh A. Culi! Z. Radmavr C. Barts-h G. Klocker H. Hittmair A ( 1995 Distant
metastases from human prostatic carcinoma express androgen receptor protein.
Cancer Res 55: '368-3072
Hobiseh A. Culig Z. Radmavr C. Bartseh G. KMoker H. Hittmair A) 1996
Androgen receptor status of I\mph node meta.stases from prostate cancer.
Prostare 28: 129-13
Horoszewicz JS. Leong SS. Ka\uinski E. Karr JP. Rosenthal H. Chu TM. Nlirand
EA. Murph! GP (1983 LNCaP model of human prostatic carcinoma. Cancer
Res 43: 1809-1819
Hsieh TC and Chiao JW- (1995) Growth moadulation of human prostatic cancer
cells b\ interleukin-I and interleukin-I receptor antagonist. CancerLer95:
19-123 _
Hsieh TC. Xu W Chiao JVi)199) Growth reeulation and cellularchanees during
differentiation of human prostatic cancer LNCaP cells as induced b\ T
l-mpho,cyte-conditioned medium. Eip Cell Res 218: 1 37-143
Isersen PO. Hart PH. Bonder CS. Lopez AF (1997) Interleutkin (IL)- 10. but not IL4
or IL-13. inhibits cytokine production and grow-th injusenile mselomonocstic
leukemia cells. CancerRes 57: 476-480
Kallio PJ. Janne OA. Palvimo JJ (1994) Agonists. but not antagonists. alter the
conformation ofthe hormone-binding domain of the androgen receptor.
Endochrinoloigv 134: 998-1001
Kemppainen JA. Lane NM SarNI. Wilson EM (1992) Androgen receptor
phosphors lation. turnover. nuclear transporL and transeriptional acti-ation.
J Biol Chem 267: 968-974
Kilian PL Kaffka KL. Biondi DA. Lipman JA. Benjamin W-R. Feldman D. Campen
CA (1991) Antiproliferatise effec-t ofinterleukin- I on human o- arian
carcinoma cell line )NIH:0'%CAXR-3 Cancer Res 51: 1823-1828
British Joumal ofCancer (1998) 78(8). 1004-1011 C) Cancer Research Campaign 1998Interleukin-1p effects onprostate tumourcells 1011
Kim IY. Kim JH. Zelner DJ. Ahn HJ. Sensibar JA. Lee C (1996) Transforming
growth factor-beta I is a mediator ofandrogen-regulated growth arrest in an
androgen-responsise prostatc cancer cell line. LNCaP Endocrinology 137:
991-999
Klein RD. Borchers AH. Sundareshan P. Bougelet C. Berkman MR Nagle RB.
Bowden GT ( 1997) Interkukinm 1 secreted from monocvtic ceUs induces the
expression of matrilysin in the prostatic cell line LNCaP JBiol Chem 272:
14188-14192
Kok-ontis i. Takakura K. Hay N. Liao S (1994) Increased androgen receptor activity
and altered c-myc expression in prostate cancer cells after long-term androgen
deprivation. Cancer Res 54: 1-1573
Lee C. Sutkowsk-i DM. SensibarJiA Zelner D. Kim L. Amsel L Shaw N. Prins GS.
Kozlowski JM (1995) Regulation ofproliferation and producion ofprostate-
specific antigen in androgen-sensitive prostate cancercells. LNCaP. bv
dihvdrotestosterone. Endocrinology 136: 796-805
Limonta P. Dondi D. Moretti RM. Maggi R. Motta M (1992) Antiproliferative
effects ofluteinizing hormone-releasing hormone agonists on the human
prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75: 207-212
Lisakl RP and Bealnear B (1991) Antibodies to intrleukin-1 inhibit cvtokine-
induced proliferation of neonatal rat Schwann cells in vitro. JNeuroimmwnol
31: 123-132
MacDonald A and Habib FK (1992) Divergent responses to epidermal growth factor
in hormone sensitive and insensitive human prostate cancer cell lines. BrJ
Cancer65: 177-182
Munoz E. Bentner U. Zubiaga A. Huber BT (1990) IL-1 activates two separate
signal transductio pathways in T helper type II cells. JImmunol 144: 964-969
Nakanoto T. ChangC. Li A. Chodak GW) 1992) Basic fibroblast growth factor in
human prostate cancercells. CancerRes 52: 571-577
Nazareth LV and Weigel NL ( 1996) Activation ofthe human androgen receptor
through protein kinase A signaling pathway. JBiol Chem 271: 19900-19907
Noordzij MA. van Weerden WM. de Ridder CM. van der Kwast TH. Schroder FH.
van Steenbrugge GJ (1996) Neuroendocrine differentiation in human prostaiic
tumor models. Am JPathol 149 859-871
Peehl DM. Wong ST. Stamey TA ( 1993) Vitamin A regulates proliferation and
differentiation ofhuman prostatic epithelial cells. Prostate 23: 69-78
Posell WC. Knox ID. NavTe M. Grogan TM. Kittelson J. Nagle RB. Bowden GT
(1993) Expression ofthe metalloproteinase matrilvsin in DU-145 cells
increases their invasive potential in severe combined immunodeficient mice.
CancerRes 53: 417-422
Ritchie CK Andrews LE. Thomas KG. Tmdall DJ. Fitzpatrick LA (1997) The
effects ofgrowth factors associated with osteoblasts on prostate carcioma
proliferation and chemotaxis: implications for the development ofmetastatic
disease. Endocrinology 138: 1145-11.50
Roberts AB. Vodovotz Y. Roche NS. Sporn MfB. Nathan CF (1992) Role ofnitric
oxide in antagonistic effects ofTGFo1 and interleukin 1 on the beatin, rate of
cultured cardiac miocoses. Mol Endocrinol 6: 1921-19)30
Salem P. Dervckx S. Dulioust A. Vivier E Denizcx Y. Damais C. Dinarello CA.
Thomas Y (1990) Immunoregulatory functions ofpaf-acether- IV.
Enhancement of IL-I production by muramyl dipeptide-stimulated monocytes.
J Immunol 144: 1338-1344
Sj6hoim A (1995) Craniide inhibits pan tic a-cell insulin prodtion and
mitogenesis and mimics the actions ofinterleuk-in-IP. FEBS Len 367: 283-286
SkowTonski RI. Peehl DM. Feldman D (1993) Vitamin D and prostate cancer 1.25
dihydroxyvitamnin D3 receptors and actions in human prostate cancer cell lines.
Endocrinologs 132: 1952-1960
Van der KwastTH. Schalken J. Ruizeveld de WimterJA. van Vroonhoven CCJ.
Mukder E. Boersma W. Trapman J (1991) Androgen receptors in endocrine-
therapy resistant prostate cancer. IntlJ Cancer48: 189-193
Vekischolte J. Ris-Stalpers C. Kuiper GGIM. Jenster G. Berresoets C. Claassen E.
van Rooij HCJ. Trapman J. Brinkmann AO. Mulder EA (1990) A mutation in
the ligand binding domain ofthe androgen receptor ofhuman LNCaP cells
affects steroid binding characteristics and response to anti-androgens. Biochem
Biophys Res Comun 173: 534-540
Venkataprasa N. Shiratsuchi H. Johnson JL Ellner JJ (1996) Induction of
prostaglandin E2 by human monocytes infected with Mvcobacterium asium
complex-modulation ofcytokine expression. JInfect Dis 174: 806-811
Walls R. Thibault A. Liu L Wood C. Kozlowski JM. Figg WI). Sampson ML Elin
RJ. Samid D (1996) The differentiating agent phenylacetate increases prostate-
specific antigen production by prostate cancer cells. Prostate 29- 177-182
Wang J. Huang M. Lee P. Komanduri K. Sharma S. Chen G. Dubinett SM (1996)
Interleukin-8 inhibits non-small cell lung cancer proliferation: a possible role
forregulation oftumor growth by autocrinc and paracrine pathways.
JInterferon Cytokine Res 16: 53-60
Wilding G. Valvenus E. Knabbe C. Gelmann EP (1989) Role oftransforminc
growth factor alpha in human prostate cancer cell grow-th. Prostate 15: 1-12
Zhao X-Y. Ly LIH Pechl DM. Feklnan D (1997) la-15-dihydroxyvitamin D3
actions in LNCaP human prostate cancer cells are androgen-dependent.
Endocrinology 138: 3290-3298
Young CY. Murtha PE. Andrew-s PE. Lindzev JK Tindall DJ I 1994) Antagonism of
androgen acton in prostate tumor cells by retinoic acid- Prostate 25: 39-45
Yuan S. Trachtenberg J. Mills GB. Brown TJ. Xu F and Keating A (1993)
Androgen-nduced inhibition ofcetl proliferation in an androgen-insensitise
prosate cancer cell line (PC-3) transfectedwith a human androgen receptor
complementaryDNA. CancerRes 53: 1304-1311
0 Cancer Research Campaign 1998 Britsh Journal ofCancer (1998) 78(8), 100C4-1O11